Abstract: The invention provides a novel ceramic-metal oxide-polymer composite material. A functionalized metal oxide nanolayer coating can be bonded between LICGCs and polymers/oligomers, which protects the LICGC from corrosion, has a low interfacial resistance to Li+ migration, and can be a SIC. Hybrid ceramic-polymer electrolytes were formed by engineering the interface between a LICGC and a polymer, polyethylene oxide (PEO), by sputter coating a 200 nm thick SiO2 layer onto a lithium ion conducting glass ceramic (LICGC) and silanating the SiO2 with a functionalized PEG in the presence of LiTFSI. A low interfacial resistance (Rinterfacial) was measured, the same as that obtained for a SiO2 interface soaked with liquid tetraglyme/LiTFSI. The pegylated SiO2 interface (unlike the tetraglyme/LiTFSI interface) protected the LICGC from corrosion by Li0 metal. The (PEG-LiTFSI)—SiO2-LICGC could be bonded with polyethylene oxide/LiTFSI.

Abstract: The present invention provides novel multi-functional (e.g., repelling biofilms, promoting formation of minerals, and having anti-infection properties) biocomposites and methods of use thereof. In various embodiments, the present invention also provides method for simultaneously treating biofilms, promoting mineralization, treating infection, or any combination thereof.

Abstract: The invention provides compositions and methods for the diagnosis, treatment, assessment, and characterization of hyperlipidemia-related diseases and disorders, including atherosclerosis, non-alcoholic fatty liver disease, obesity and diabetes mellitus in a subject in need thereof, based on the expression level of at least one miRNA that is associated with these diseases and disorders.

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and/or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and/or biofilm-embedded microorganisms on a surface.

Abstract: Identification of BAG3 (Bcl2-associated anthanogene 3) genetic variants were associated with the prevalence non-ischemic or ischemic dilated cardiomyopathy (DCM) and DCM outcomes in individuals of African ancestry.

Abstract: The present invention is related to compositions and methods for treating platelet-related diseases.

Abstract: Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile.

Abstract: The present invention provides for the first time the identification of fetal neural exosomal biomarkers isolated from maternal plasma useful in diagnosing fetal neurodevelopmental outcomes. The invention also provides the identification of neonatal neural exosomal biomarkers isolated from neonatal plasma useful in diagnosing neonatal neurodevelopmental outcomes The present invention therefore provides methods, kits and systems for diagnosing fetal neurodevelopmental outcomes, by examining relevant proteins and RNA in fetal neural exosomes isolated from a maternal plasma and neonatal neural exosomes isolated from neonatal plasma.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

Abstract: The present invention includes novel bridged bicycloalkyl-substituted aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

Abstract: Methods of eliminating a retrovirus from a subject utilize nanoformulated anti-retroviral compounds and gene editing agents. Compositions comprise at least one anti-retroviral compounds, at least one gene-editing agent, or combinations thereof.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing type 2 diabetes, pre-diabetes and conditions characterized by an increase in the levels of A1C, glucose, insulin, homeostasis model of assessment of insulin resistance HOMA-IR), oxidative stress in adipose tissue, and earbonvlation of GLUT4 comprising administering an effective amount of a compound of Formula I-III as described herein, to a subject in need thereof.

Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Abstract: The present invention provides homologous recombination vectors to insert transgenic DNA in cells. These vectors shorten the production time and allow for easy generation of genetically modified cells. The invention allows the user to test multiple tags and to generate homozygous modified cell line using the homologous recombination vector. The invention can be used to generate knockout cells, to generate cell lines with knockin genes, to generate cell lines for drug screening against any target, to create transgenic animals, or in gene therapy.

Abstract: The present invention relates to methods and compositions for water treatment and environmental remediation using nanoparticle supported lipid bilayers (NP-SLBs). In one embodiment, the NP-SLBs are single or multilayer lipid bilayers of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) supported by silica.

Abstract: This invention is generally related to novel compositions for treating or preventing heart failure. Specifically, the disclosure provides a composition comprising an amino-terminal domain of Beta.adrenergic receptor kinase-1 (Beta.ARKnt) peptide, or a nucleic acid encoding Beta.ARKnt. Further disclosed are methods of using the compositions for treating or preventing heart failure in a subject or for altering Beta.-adrenergic receptor (Beta.AR) density in a subject.